

VTE Guideline Committee Meeting 1

Date: 2nd March 2023

Location: Virtual Meeting via Zoom

Minutes: Confirmed

Committee members present:				
Susan Harrison (SH) Chair	Present for all items			
Anne Byrne	Present for all items			
Colin Church	Present for all items			
Deepa Gopalan	Present for all items			
Beverley Hunt	Present for all items			
Graham Lloyd Jones	Present for all items			
Terry McCormack	Present for all items			
Lara Roberts	Present for all items			
Huw Rowswell	Present for all items			
Astrid Ullrich-Boereboom	Present for all items			

In attendance:					
Victoria Axe	Guideline Commissioning Manager	Present for all items			
Elizabeth Barrett	Information Specialist	Present for all items			
Sarah Boyce (SB)	Technical Analyst	Present for all items			
Lindsey Claxton (LC)	Technical Adviser (Health Economics)	Present for all items			
Debra Hunter	Project Manager	Present for all items			
Kate Kelley	GDT-B Associate Director	Present for all items			
Emma McFarlane (EMF)	Technical Adviser	Present for all items			
Annette Mead	Senior Medical Editor	Present for Items 1-5			
Cheryl Pace	Implementation Manager	Present for all items			
Natasha Salant (NS)	Technical Analyst (Health Economics)	Present for all items			
Philip Williams	Resource Impact Lead	Present for all items			
Maria Majeed	NICE Observer	Present for items 1-5			

Apologies:	
Dan Horner	Vascular Disease Physician
Nigel Langford	General Physician



1 & 2. Welcome and Introductions and Declaration of interest

The Chair (SH) welcomed the committee members and NICE attendees to the first committee meeting for the Venous thromboembolic diseases: diagnosis, management and thrombophilia testing guideline update. SH informed attendees that apologies had been received, these are noted above.

SH asked all committee members and attendees to introduce themselves and to verbally declare any new interests not listed on the registry. The following interest was declared:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Dr Graham Lloyd- Jones	Consultant Radiologist- Specialising in General, Emergency, Chest and Musculoskeletal Imaging Salisbury NHS Foundation Trust.	Co-investigator radiologist for REACT COVID-19 research group based at University Hospital Southampton Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study	Non- Financial professional and personal	Declare and participate. Rationale: interest is nonspecific.

3. Overview of Review process and presentation of clinical evidence

The Chair introduced Sarah Boyce (SB), Senior Technical Analyst who gave the committee an introductory overview of the NICE evidence review process and presented the clinical evidence for the review questions: in people with COVID-19 and suspected PE, and in people with COVID-19 and suspected DVT, can we safely rule out the need for further imaging based on a combination of clinical probability score and D-dimer assay?

The Chair thanked SB for the presentation and the committee for their input.

4. Health Economic Presentation

SH introduced Lindsay Claxton (LC), Health Economic Adviser and Natasha Salant (NS), Health Economic Analyst, who presented the health economic evidence for the 2 review questions to the Committee.

The Chair thanked LC and NS for the presentation and the committee for their input.

5. Committee Discussion

The Chair facilitated discussion amongst the Committee and NICE staff.

6. Recommendation Drafting

SB facilitated discussion and review of the existing recommendations; some recommendations were updated



7. Equalities Impact Assessment

Emma McFarlane (EMF), Technical Adviser gave the committee an overview of the Equality impact assessment (EIA) for the guideline and asked for input on whether any changes or additions are needed.

The Chair thanked EMF for her presentation and the committee for their input.

8. PERC Update

EMF outlined proposals for the Pulmonary Embolism Rule-out Criteria (PERC) recommendation refresh.

The Chair thanked EMF for her presentation and the committee for their input.

8. Summary of the day and next steps

The Chair confirmed the next steps for the guideline development, and date for next meeting, the Chair thanked the committee for their contributions and asked for items of any other business. As there was no further business to discuss, the Chair brought the meeting to a close.

Date of next meeting: 24/3/23

Location of next meeting: Virtual